Qiming-Backed AI Drug Discovery Startup Insilico Medicine Hits Unicorn Status With $110 Million Funding Round

Insilico raises $110m for AI-designed drug pipeline

Insilico Medicine has raised $110 million in Series E funding for its artificial intelligence-powered drug discovery operations.

Qiming-Backed AI Drug Discovery Startup Insilico Medicine Hits Unicorn Status With $110 Million Funding Round

Insilico Medicine, whose Hong Kong IPO application lapsed in 2024, is still considering going public in the city, said founder Alex Zhavoronkov.

AI Drug Startup Insilico Weighs Hong Kong IPO After New Funding

Insilico Medicine Inc. is considering an initial public offering after securing funding at a valuation of more than $1 billion, reflecting growing interest in the potential use of AI to discover ground-breaking new drugs.

Insilico raises $110m to develop drug pipeline and AI platform

Insilico Medicine has completed a Series E round, raising $110m to progress the development of its pipeline of drugs and AI platform.

Insilico Medicine scores $110M for AI-enabled drug discovery

Tech-enabled drug discovery company Insilico Medicine secured $110 million in an oversubscribed Series E funding round.   A large equity fund of Value Partners Group, an asset management firm in Asia, and new and existing investors participated in the round. WHAT IT DOES Massachusetts-based Insilico's proprietary generative AI platform, Pharma.AI, utilizes biology, clinical medicine, scientific research and generative chemistry for drug discover…

Insilico Medicine Raises $110M in Series E Financing

Insilico Medicine, a Cambridge, MA-based clinical-stage generative artificial intelligence (AI)-driven drug discovery company, raised $110M in Series E funding. The round was led by Value Partners Group (HKG:0806) with participation from new and existing investors. The company intends to use the fund to advance innovative drug pipeline and AI platform developments. On one side, resources […] The post Insilico Medicine Raises $110M in Series E Fi…